Verbatim response from ChatGPT
Short answer
- Expect gradual, not overnight, weight loss. Typical results are roughly 5–10% of body weight in the first 3–4 months, and 10–20% or more after about 6–12 months depending on the drug and dose.
- Weight loss is usually maintained only while you continue treatment plus lifestyle changes — stopping the drug commonly leads to partial or full regain.
How fast (typical examples)
- Semaglutide (Wegovy, brand for obesity; Ozempic is the diabetes brand of semaglutide): clinical trials with Wegovy (2.4 mg) showed average weight loss around ~15% of baseline at about 68 weeks. Many people see several percent of weight loss in the first few months.
- Tirzepatide (Zepbound is the obesity brand; Mounjaro is the diabetes brand of tirzepatide): trials (SURMOUNT) showed larger average losses than semaglutide in many participants — in the high-dose groups average losses approached ~20% or a little more at ~72 weeks.
- Individual response varies a lot — some people lose more, some less. Dose, adherence, initial body weight, metabolism, other medications, and lifestyle all matter.
Why it takes time
- These drugs reduce appetite and slow gastric emptying; it takes weeks for dose escalation and for the full appetite/weight effect to appear. Initial weight loss also includes some fluid and glycogen changes; sustainable fat loss is gradual.
Sustainability
- Evidence so far: continuing the medication with ongoing lifestyle support keeps weight down. Stopping the medication commonly leads to weight regain toward baseline over months to years unless other intensive measures are used. In other words, for many people GLP-1 or GIP/GLP-1 drugs are highly effective long-term therapies, but they are usually a chronic (ongoing) treatment rather than a short-course cure.
- Combining medication with dietary changes, physical activity, sleep optimization, and behavioral support improves long-term outcomes and can reduce the degree of regain after stopping.
Risks and monitoring
- Common side effects: nausea, vomiting, constipation, diarrhea, loss of appetite. These are usually worst during dose escalation.
- Important contraindications: personal or family history of medullary thyroid carcinoma or MEN2 (ask your doctor), pregnancy or planning pregnancy, certain GI disorders, history of pancreatitis — discuss with a clinician.
- You’ll need medical monitoring (weight, blood pressure, glucose, possibly labs) and a plan for side-effect management and follow-up.
Practical next steps (who/where to go)
- See your primary care doctor or an obesity medicine specialist (look up the American Board of Obesity Medicine physician finder) to discuss whether GLP-1/GIP drugs are appropriate.
- If you prefer telehealth options (for convenience or access), reputable services that provide clinician evaluations for weight management include Ro (Roman), Hims & Hers, and PlushCare — they can evaluate and prescribe when appropriate. Always confirm they connect you with a licensed clinician and provide follow-up.
- For affordability: check manufacturer savings programs (Novo Nordisk has patient support for Wegovy/Ozempic; Eli Lilly has support for Zepbound/Mounjaro) and discount services like GoodRx to compare prices. Your insurance plan and prior-authorization rules make a big difference.
Bottom line GLP-1 and GIP/GLP-1 drugs can produce meaningful weight loss fairly quickly relative to dieting alone, but results vary and are typically maintained only while treatment continues and lifestyle changes are made. Talk with a clinician (preferably an obesity specialist or your PCP) to review benefits, risks, cost, and a long-term plan tailored to you. If you want, tell me your current weight, goals, medical history (esp. pregnancy plans, pancreatitis, thyroid cancer family history), and whether you have insurance — I can give a more personalized estimate and next-step suggestions.